Real-world effectiveness of palbociclib in HR+/HER2- metastatic breast cancer: a literature review
Approximately 70% of newly diagnosed breast cancers are of the HR+/HER2- subtype. For the treatment of patients with HR+/HER2- metastatic breast cancer, current guidelines recommend the use of a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib) in combination with endocrine therapy. In this...
Enregistré dans:
| Auteurs principaux: | , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Taylor & Francis Group
2024-12-01
|
| Collection: | Future Science OA |
| Sujets: | |
| Accès en ligne: | https://www.tandfonline.com/doi/10.2144/fsoa-2023-0074 |
| Tags: |
Pas de tags, Soyez le premier à ajouter un tag!
|